Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
In reviewing the safety of various medications for patients with heart failure, Amabile and Spencer1 have provided clinicians with an excellent resource. Although they offer the disclaimer that their review is not exhaustive, they have omitted an exceptionally important cause of drug-related harm in patients with heart failure.
In appropriate patients, spironolactone improves cardiac morbidity and mortality with a relatively low incidence of hyperkalemia.2 However, the reality is that spironolactone is often prescribed to patients with additional risk factors (drug and nondrug) for hyperkalemia, with inadequate clinical and laboratory monitoring, and sometimes to patients with no clear indication for the drug to begin with.3 While several reports describe life-threatening hyperkalemia resulting from the combination of spironolactone and angiotensin-converting enzyme inhibitors, highlighting this drug interaction for clinicians,4- 8 they tell us nothing of the sudden prehospital deaths from hyperkalemia that might simply have been ascribed to heart disease.
Juurlink DN, Hansten PD. Drug Safety in Patients With Heart Failure. Arch Intern Med. 2005;165(1):118. doi:10.1001/archinte.165.1.118-a